REDHILL B.S.ADR 10/IL-,01 Forum: Community User: MeisterYoda1

+35Mio Aktien oder + Aktien im Werr von 35Mio kamen heute raus?

2250 stk.

Ich bin bei 1500 nun. Hab Geld freigeschaufelt um heute den EK zu drücken. Wie gesagt, es war sehr verlockend. Hier muss man aber Atem mitbringen. Zulassung Produktion etc alles 2. Quartal.

Mit wieviel Anteilen seid ihr dabei? Ich habe heute meinen EK noch was gedrückt und bin bei 500

Hab heute auch meinen EK drücken können.

Dann kann die Reise jetzt beginnen! Es kommen spannende Wochen.

Bin jetzt auch mit über 8000 Aktien dabei, der Kurs war mir zu niedrig um nicht einzusteigen!👍

Das sind doch mal News! 👌🏼👍🏽

RHB-107 is a novel, orally-administered serine protease inhibitor with antiviral and potential tissue-protective effects which targets human cells rather than the virus itself and is expected to be effective against new viral strains. The two-part randomized, double-blind, placebo-controlled hybrid U.S. Phase 2/3 study is enrolling more than 300 patients with symptomatic COVID-19, who do not require hospital care, to evaluate the safety and effectiveness of RHB-107. Patients will be sent home with RHB-107 and five 510(k)-cleared devices to begin treatment. ObvioHealth's platform is collecting both telemetric and patient-reported information; biomarkers continuously gathered from the devices will include patients' temperature, respiratory and pulse rates, blood pressure, pulse oximetry, electrocardiogram (ECG) and weight. "Many previous COVID-19 treatment studies have focused on intravenous medications for hospitalized patients. However, the majority of patients are battling the virus at home. The ability to treat patients early in the course of the COVID-19 disease, with an oral therapy that shows promise against emerging viral variants and is designed to be used outside the hospital, has the potential to be a game-changer in managing this disease," said Dr. Terry Plasse, Medical Director for RedHill Biopharma. "Until recently, it was assumed that patients needed to travel to clinical sites for assessments of vital signs. However, inroads in the development of accurate and 510(k)-cleared medical devices for in-home use enable patients in clinical trials to do much of this from home." A recent study evaluating RHB-107's antiviral activity in an in vitro model of human lung bronchial tissue showed potent inhibition of SARS-CoV-2 viral replication. Its combined antiviral and potential tissue-protective action make it a strong candidate for evaluation as a treatment for COVID-19 infections. Home healthcare nurses will make in-home visits to check-in on patients, collect blood samples for certain laboratory parameters, perform virus PCR swabs at home, and oversee certain patient-reported data capture, using devices provided to participants at home. This combined level of medical monitoring allows the study team to intervene quickly if a patient experiences an adverse event. "Clinical studies involving COVID-19 patients introduce significant risks, requiring constant monitoring and careful practices to avoid exposure to the virus. This innovative trial allows participants to remain quarantined during treatment while remotely providing valuable data to researchers, reducing risk of spread," says Ivan Jarry, CEO of ObvioHealth. "The unique needs brought on by the pandemic have opened up a world of opportunity for more convenient capture of real-world data and we anticipate growing interest in these more comprehensive remote clinical trials due to their efficiency and ease for participants."

NEW YORK, March 2, 2021 -- ObvioHealth, a global virtual research organization or VRO, today announced the launch of a hybrid clinical trial for the treatment of COVID-19, using an innovative study design with digital data capture to remotely monitor patient vitals. This U.S. Phase 2/3 study will examine the safety and efficacy of RedHill Biopharma's (Nasdaq: RDHL) RHB-107 (upamostat), using ObvioHealth's clinical trial ecosystem, including digital devices, a patient-centric smartphone application and home healthcare visits.

Hab jetzt so viel nachgelegt dass es zur größten Position in meinem Depot wurde. Hätte ich vor 24 Stunden auch nicht gedacht aber ich glaub an die Firma und der Preis war jetzt echt verlockend

Veräußerung auf 35 Millionen Dollar erhöht. Buy the dip :)

...kleiner Absturz, Nachgelegt!

Es gibt Vermutungen, dass die Nachfrage nach Opaganib - zur Behandlung von Post COVID - sehr viel höher ist als vermutet und mit dem Geld die Kapazitäten für die Produktion hoch gefahren werden könnten. Das natürlich wenn es als covid Medikament zugelassen wird. Da sieht es ja auch gut aus. Also kann alles im Nachhinein eine gute Geschichte sein. Das ist ein Szenario worüber Vermutungen angestellt werden

https://www.sec.gov/Archives/edgar/data/0001553846/000117891321000843/zk2125661.htm

Danke für eure Meinung. 👍🏻